Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration

Abstract Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular degeneration (nAMD). These outcomes were was as...

Full description

Saved in:
Bibliographic Details
Main Authors: Federico Beretta, Ilaria Zucchiatti, Riccardo Sacconi, Federico Fantaguzzi, Stefano Lingardo, Francesco Bandello, Giuseppe Querques
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Ophthalmology and Therapy
Subjects:
Age-related macular degeneration
Anti-vascular endothelial growth factor
Brolucizumab
Fluid analysis
Intraocular inflammation
Switch therapy
Online Access:https://doi.org/10.1007/s40123-025-01141-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40123-025-01141-y

Similar Items